Large Inflow of Money Detected in Novartis AG

Novartis AG (NVS) : Thursdays money flow data in Novartis AG (NVS) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $14.48 million, whereas, $12.44 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.16, in favor of the bulls. The total money flow into the stock was $2.04 million clearly indicating that the smart money has been buying into the stock on weakness.

In comparison, the money flow in block deals was $1.09 million. The total value of block trades done on upticks was $1.09 million. Novartis AG (NVS) fell $0.05 and traded at $81.98, down -0.06% for the day, over previous days close. On a weekly basis, the shares are -0.18% over the previous weeks close.


The stock has recorded a 20-day Moving Average of 2.29% and the 50-Day Moving Average is 4.38%. Shares have dropped -22.29% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $106.84 and the one year low was seen on Apr 1, 2016. The 50-Day Moving Average price is $79.86 and the 200 Day Moving Average price is recorded at $77.09.

Novartis AG (NYSE:NVS): The stock opened at $81.83 on Thursday but the bulls could not build on the opening and the stock topped out at $82.07 for the day. The stock traded down to $81.74 during the day, due to lack of any buying support eventually closed down at $82.02 with a loss of -0.01% for the day. The stock had closed at $82.03 on the previous day. The total traded volume was 1,000,872 shares.

Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.